Fight Aging! Newsletter, April 20th 2020

In conclusion, elevated brain amyloid was associated with family history and APOE ε4 allele but not with multiple other previously reported risk factors for AD. Elevated amyloid was associated with lower test performance results and increased reports of subtle recent declines in daily cognitive function. These results support the hypothesis that elevated amyloid represents an early stage in the Alzheimer's continuum. Blood Metabolites as a Marker of Frailty https://www.fightaging.org/archives/2020/04/blood-metabolites-as-a-marker-of-frailty/ Frailty in older people is usually diagnosed in a symptomatic way, by assessment of physical weakness. The condition has other components, however, such as chronic inflammation, cognitive decline, greater immune dysfunction, and so forth. Researchers here produce a biomarker for frailty based on a selection of metabolites in blood. This is a step towards a more rigorous class of test that might be able to pick out those in the earlier stages of frailty who are more likely to progress absent some form of intervention, such as strength training or therapies like senolytics that will reduce the burden of inflammation. Researchers looked at 19 elderly patients, all above the age of 75, and measured whether they suffered from frailty through three clinical analysis tests - the Edmonton frail scale (EFS), the Montreal cognition assessment (MoCA-J), and the Timed Up and Go Test (TUG). "Both the EFS and the MoCA-J ga...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs